Nasal drug delivery in humans

Current Problems in Dermatology

Volumn 40, Issue , 2011, Pages 20-35

  Bitter, Christoph ^a   Suter Zimmermann, Katja ^a   Surber, Christian ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Universitatsspital Basel Dermatologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BUSERELIN; BUTORPHANOL; CALCITONIN; CARRIER PROTEIN; CHITOSAN; DESMOPRESSIN; DIAZEPAM; ESTRADIOL; FENTANYL; GONADORELIN; HUMAN GROWTH HORMONE; INFLUENZA VACCINE; INSULIN; KETAMINE; LEVODOPA; MELATONIN; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; NAFARELIN; NICOTINE; OXYTOCIN; PROGESTERONE; SILDENAFIL; SUMATRIPTAN; TESTOSTERONE; ZOLMITRIPTAN;

ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG STABILITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOSE; NOSE CAVITY; OSMOLALITY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; VASOCONSTRICTION; VASODILATATION;

ADMINISTRATION, INTRANASAL; BLOOD-BRAIN BARRIER; CARDIOVASCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; NASAL CAVITY; NASAL MUCOSA; P-GLYCOPROTEINS; PHARMACEUTICAL VEHICLES; VACCINES;

EID: 84906768961     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000321044     Document Type: Article

References (69)

1. Shyeilla VD, Leah RH, William HF II: Intranasal delivery to the central ner-vous system: mechanisms and experi-mental considerations. J Pharm Sci 2010;99:1654-1673.
2. Merkus FW, van den Berg MP: Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs R D 2007;8:133-144. (Pubitemid 46707837)
3. Ugwoke MI, Exaud S, van den Mooter G, Verbeke N, Kinget R: Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur J Pharm Sci 1999;9:213-219. (Pubitemid 30012078)
4. Kendirci M, Hellstrom WJ: Intranasal apomorphine. Nastech Pharm Drugs 2004;7:483-488.
5. Junginger HE, Thanou M, Luessen HL, Kotze AF, Verhoef JC: Safe mucosal pen-etration enhancers-a fiction? Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) 1999;40: 261-262.
6. Dale O, Hjortkjaer R, Kharasch ED: Nasal administration of opioids for pain management in adults. Acta Anaesthe-siol Scand 2002;46:759-770. (Pubitemid 34803193)
7. Hinchcliffe M, Jabbal-Gill I, Smith A: Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. J Pharm Pharmacol 2005;57:681-687. (Pubitemid 40694875)
8. Van Asselt DZ, Merkus FW, Russel FG, Hoefnagels WH: Nasal absorption of hydroxocobalamin in healthy elderly adults. Br J Clin Pharmacol 1998;45:83-86. (Pubitemid 28062859)
9. Lopes T, Dias JS, Marcelino J, Varela J, Ribeiro S, Dias J: An assessment of the clinical efficacy of intranasal desmopres-sin spray in the treatment of renal colic. BJU Int 2001;87:322-325. (Pubitemid 32240842)
10. Li L, Nandi I, Kim KH: Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm 2002;237:77-85. (Pubitemid 34310481)
11. Wang X, Chi N, Tang X: Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008; 70:735-740.
12. Van den Berg MP, Verhoef JC, Romeijn SG, Merkus FW: Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 2004;58: 131-135. (Pubitemid 38781013)
13. Christrup LL, Foster D, Popper LD, Troen T, Upton R: Pharmacokinetics, efficacy and tolerability of fentanyl fol-lowing intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy two-way crossover study. Clin Ther 2008;30:469-481. (Pubitemid 351483922)
14. Arora P Sharma S, Garg S: Permeability issues in nasal drug delivery Drug Dis-cov Today 2002;7:967-975. (Pubitemid 35286901)
15. Leitner VM, Guggi D, Krauland AH, Bernkop-Schnurch A: Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J Con-trol Release 2004;100:87-95. (Pubitemid 39445988)
16. Sharma S, Mukkur TK, Benson HA, Chen Y: Pharmaceutical aspects of intra-nasal delivery of vaccines using particu-late systems. J Pharm Sci 2009;98:812-843.
17. Yu S, Zhao Y, Wu F, Zhang X, Lu W, Zhang H, Zhang Q: Nasal insulin deliv-ery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 2004;281: 11-23. (Pubitemid 39024259)
18. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, Green G, Albin R, Hamilton D, Rogers MC: Safety and efficacy of intranasal ket-amine for the treatment of breakthrough pain in patients with chronic pain: a ran-domized, double-blind, placebo-controlled, crossover study. Pain 2004; 108:17-27. (Pubitemid 38251669)
19. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A: Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water sol-uble prodrugs. Pharm Res 2000;17:978-984.
20. Van den Berg MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW: Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. Pharm Res 2004;21:799-802. (Pubitemid 39011303)
21. Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H: Nasal absorp-tion of metoclopramide from different Carbopol® 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 2006;64:246-254. (Pubitemid 44308522)
22. Gavini E, Rassu G, Muzzarelli C, Cossu M, Giunchedi P: Spray-dried micro-spheres based on methylpyrrolidinone chitosan as new carrier for nasal admin-istration of metoclopramide. Eur J Pharm Biopharm 2008;68:245-252.
23. Tschirch FT, Suter K, Froehlich JM, Stu-dler U, Nidecker A, Eckhardt B, Beranek-Chiu J, Surber C, Weishaupt D: Multicenter trial: comparison of two different formulations and application systems of low-dose nasal midazolam for routine magnetic resonance imaging of claustrophobic patients. J Magn Reson Imaging 2008;28:866-872.
24. Haschke M, Suter K, Hofmann S, Witschi R, Frohlich J, Imanidis G, Drewe J, Briellmann TA, Dussy FE, Krahenbuhl S, Surber C: Pharmacokinetics and phar-macodynamics of nasally delivered midazolam. Br J Clin Pharmacol 2010; 69:607-616.
25. Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS: Intranasal delivery of mor-phine. J Pharmacol Exp Ther 2002;301: 391-400.
26. Avrech OM, Goldman GA, Pinkas H, Amit S, Neri A, Zukerman Z, Ovadia J, Fisch B: Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial. Gynecol Endocrinol 1996;10:165-170. (Pubitemid 26232186)
27. Jung BH, Chung BC, Chung SJ, Lee MH, Shim CK: Prolonged delivery of nicotine in rats via nasal administration of proli-posomes. J Control Release 2000;66:73-79. (Pubitemid 30116686)
28. Hurlemann R, Patin A, Onur OA, Cohen MX, Baumgartner T, Metzler S, Dziobek I, Gallinat J, Wagner M, Maier W, Kend-rick KM: Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J Neurosci 2010;30:4999-5007.
29. Elshafeey AH, Bendas ER, Mohamed OH: Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rab-bits. AAPS Pharm Sci Tech 2009;10:361-367.
30. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS: Thermoreversible- mucoadhesive gel for nasal delivery of sumatriptan. AAPS Pharm Sci Tech 2006;7:67.
31. Hussain AA, Al-Bayatti AA, Dakkuri A, Okochi K, Hussain MA: Testosterone 17beta-N,N-dimethylglycinate hydro-chloride: a prodrug with a potential for nasal delivery of testosterone. J Pharm Sci 2002;91:785-789. (Pubitemid 34639642)
32. Diener HC, Evers S: Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study. Clin Drug Invest 2007;27:59-66. (Pubitemid 46061386)
33. Jain R, Nabar S, Dandekar P, Patravale V: Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy Pharm Res 2010;27: 655-664.
34. Rogers DF: Physiology of airway mucus secretion and pathophysiology of hyper-secretion. Respir Care 2007;52:1134-1146, discussion 1146-1139.
35. Seaton A, MacNee W, Donaldson K, Godden D: Particulate air pollution and acute health effects. Lancet 1995;345: 176-178.
36. Pires A, Fortuna A, Alves G, Falcao A: Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2009;12: 288-311.
37. Marttin E, Verhoef JC, Schipper NG, Merkus FW: Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13-38. (Pubitemid 28045041)
38. Costantino HR, Illum L, Brandt G, John-son PH, Quay SC: Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24. (Pubitemid 46756063)
39. Mathias NR, Hussain MA: Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 2009;99:1-20.
40. Donovan MD, Huang Y: Large molecule and particulate uptake in the nasal cav-ity: the effect of size on nasal absorption. Adv Drug Deliv Rev 1998;29:147-155. (Pubitemid 28044091)
41. Amidon GL, Lennernas H, Shah VP, Crison JR: A theoretical basis for a biop-harmaceutic drug classification: the cor-relation of in vitro drug product dissolu-tion and in vivo bioavailability Pharm Res 1995;12:413-420.
42. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computa-tional approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25. (Pubitemid 27046991)
43. Ugwoke MI, Agu RU, Verbeke N, Kinget R: Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-1665. (Pubitemid 41443473)
44. Davis SS, Illum L: Absorption enhancers for nasal drug delive?-Clin Pharma-cokinet 2003;42:1107-1128. (Pubitemid 37357648)
45. Verse T, Sikora C, Rudolph P, Klocker N: The tolerability of nasal drugs with spe-cial regard to preservatives and physico-chemical parameters (in German). Lar-yngorhinootologie 2003;82:782-789. (Pubitemid 37486568)
46. Illum L: Chitosan and its use as a phar-maceutical excipient. Pharm Res 1998; 15:1326-1331. (Pubitemid 28427917)
47. Vidgren MT, Kublik H: Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-177. (Pubitemid 28044092)
48. Scheibe M, Bethge C, Witt M, Hummel T: Intranasal administration of drugs. Arch Otolaryngol Head Neck Surg 2008; 134:643-646. (Pubitemid 351871026)
49. Dhanda DS, Frey WH II, Leopold D, Kompella UB: Approaches for drug depo-sition in the human olfactory epithelium. Drug Deliv Technol 2005;5:64-72.
50. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, 2nd, Craft S: Intranasal insulin administration dose-dependently modu-lates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008;13:323-331. (Pubitemid 352039034)
51. Hallschmid M, Benedict C, Schultes B, Perras B, Fehm HL, Kern W, Born J: Towards the therapeutic use of intrana-sal neuropeptide administration in met-abolic and cognitive disorders. Regul Pept 2008;149:79-83.
52. Dhuria SV, Hanson LR, Frey WH II: Novel vasoconstrictor formulation to enhance intranasal targeting of neuro-peptide therapeutics to the central ner-vous system. J Pharmacol Exp Ther 2009;328:312-320.
53. Schinkel AH: The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8:161-170. (Pubitemid 28041013)
54. Graff CL, Pollack GM: Functional evi-dence for P-glycoprotein at the nose-brain barrier. Pharm Res 2005;22:86-93. (Pubitemid 40558150)
55. Slutter B, Hagenaars N, Jiskoot W: Ratio-nal design of nasal vaccines. J Drug Tar-get 2008;16:1-17.
56. Aguilar JC, Rodriguez EG: Vaccine adju-vants revisited. Vaccine 2007;25:3752-3762.
57. Csaba N, Garcia-Fuentes M, Alonso MJ: Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61:140-157.
58. Kammona O, Alexopoulos AH, Karako-sta P, Kotti K, Karageorgiou V, Kiparissi-des C: Nanocarrier aided nasal vaccina-tion: an experimental and computational approach. Ind Eng Chem Res 2010, DOI: 10.1021/ie100307t.
59. Olmsted SS, Padgett JL, Yudin AI, Wha-ley KJ, Moench TR, Cone RA: Diffusion of macromolecules and virus-like par-ticles in human cervical mucus. Biophys J 2001;81:1930-1937. (Pubitemid 32917145)
60. Cone RA: Barrier properties of mucus. Adv Drug Deliv Rev 2009;61:75-85.
61. Hancock BC, Zografi G: Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1-12.
62. Hancock BC, Parks M: What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17: 397-404. (Pubitemid 30395293)
63. Hilden LR, Morris KR: Physics of amor-phous solids. J Pharm Sci 2004;93:3-12.
64. Matteucci ME, Miller MA, Williams RO, Johnston KP: Highly supersaturated solutions of amorphous drugs approach-ing predictions from configurational thermodynamic properties. J Phys Chem 2008;112:16675-16681.
65. Yang W, Johnston KP, Williams RO 3rd: Comparison of bioavailability of amor-phous versus crystalline itraconazole nanoparticles via pulmonary adminis-tration in rats. Eur J Pharm Biopharm 2010;75:33-41.
66. Yang C, Gao H, Mitra AK: Chemical sta-bility enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir. J Pharm Sci 2001;90:617-624. (Pubitemid 32378383)
67. Surber C, Smith EW: The mystical effects of dermatological vehicles. Der-matology 2005;210:157-168. (Pubitemid 40463206)
68. Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C: Effect of concentra-tion and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo avail-ability on human skin. Pharm Res 1999; 16:909-915. (Pubitemid 29284204)
69. Djupesland PG, Skretting A, Winderen M, Holand T: Bi-directional nasal deliv-ery of aerosols can prevent lung deposi-tion. J Aerosol Med 2004;17:249-259. (Pubitemid 39299326)